Trexquant Investment LP Takes Position in Enfusion, Inc. (NYSE:ENFN)

Trexquant Investment LP acquired a new position in Enfusion, Inc. (NYSE:ENFN) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 58,681 shares of the company’s stock, valued at approximately $604,000.

Other institutional investors have also added to or reduced their stakes in the company. KLP Kapitalforvaltning AS bought a new position in Enfusion during the 4th quarter worth approximately $75,000. Quantbot Technologies LP bought a new position in Enfusion during the fourth quarter worth $144,000. Intech Investment Management LLC acquired a new position in Enfusion in the fourth quarter valued at $191,000. Fox Run Management L.L.C. acquired a new position in Enfusion in the fourth quarter valued at $265,000. Finally, Rhumbline Advisers boosted its position in Enfusion by 3.0% during the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after acquiring an additional 1,796 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.

Enfusion Price Performance

ENFN stock opened at $10.81 on Friday. Enfusion, Inc. has a 1 year low of $7.83 and a 1 year high of $11.80. The company’s 50-day moving average is $11.11 and its 200-day moving average is $10.37. The stock has a market capitalization of $1.39 billion, a PE ratio of 270.19, a price-to-earnings-growth ratio of 1.85 and a beta of 0.92.

Enfusion (NYSE:ENFN) last issued its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The firm had revenue of $52.94 million during the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. On average, analysts anticipate that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Enfusion

In other news, insider Bronwen Bastone sold 3,126 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total value of $35,573.88. Following the completion of the sale, the insider now owns 221,875 shares in the company, valued at $2,524,937.50. This represents a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Oleg Movchan sold 11,452 shares of Enfusion stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $11.39, for a total transaction of $130,438.28. Following the transaction, the chief executive officer now directly owns 631,847 shares in the company, valued at approximately $7,196,737.33. This represents a 1.78 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 67,860 shares of company stock worth $772,015. Insiders own 36.44% of the company’s stock.

Analyst Ratings Changes

ENFN has been the topic of a number of recent analyst reports. Stifel Nicolaus boosted their price objective on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. William Blair reissued a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Piper Sandler increased their price target on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.